152 related articles for article (PubMed ID: 35788257)
1. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.
Larkin KT; Nicolet D; Kelly BJ; Mrózek K; LaHaye S; Miller KE; Wijeratne S; Wheeler G; Kohlschmidt J; Blachly JS; Mims AS; Walker CJ; Oakes CC; Orwick S; Boateng I; Buss J; Heyrosa A; Desai H; Carroll AJ; Blum W; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Stone RM; Paskett ED; Byrd JC; Mardis ER; Eisfeld AK
Blood Adv; 2022 Oct; 6(19):5570-5581. PubMed ID: 35788257
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center.
Jaime-Pérez JC; Padilla-Medina JR; Fernández LT; Herrera-Garza JL; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):286-292. PubMed ID: 29478946
[TBL] [Abstract][Full Text] [Related]
3. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
Niederwieser C; Nicolet D; Carroll AJ; Kolitz JE; Powell BL; Kohlschmidt J; Stone RM; Byrd JC; Mrózek K; Bloomfield CD
Haematologica; 2016 Dec; 101(12):1516-1523. PubMed ID: 27470602
[TBL] [Abstract][Full Text] [Related]
4. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
5. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
Pemmaraju N; Kantarjian H; Ravandi F; Nogueras-Gonzalez GM; Huang X; O'Brien S; Wierda W; Garcia-Manero G; Thomas D; Pierce S; Verstovsek S; Borthakur G; Cortes J
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):213-222.e2. PubMed ID: 26838606
[TBL] [Abstract][Full Text] [Related]
6. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
7. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
8. Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.
Bhatnagar B; Kohlschmidt J; Mrózek K; Zhao Q; Fisher JL; Nicolet D; Walker CJ; Mims AS; Oakes C; Giacopelli B; Orwick S; Boateng I; Blachly JS; Maharry SE; Carroll AJ; Powell BL; Kolitz JE; Stone RM; Byrd JC; Paskett ED; de la Chapelle A; Garzon R; Eisfeld AK
Cancer Discov; 2021 Mar; 11(3):626-637. PubMed ID: 33277314
[TBL] [Abstract][Full Text] [Related]
9. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
10. Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience.
Rubnitz JE; Lensing S; Razzouk BI; Pounds S; Pui CH; Ribeiro RC
Pediatr Blood Cancer; 2007 Jan; 48(1):10-5. PubMed ID: 16642489
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Kanamori H; Usuki K; Uoshima N; Yanada M; Takeuchi J; Mizuno I; Kanda J; Okamura H; Yano S; Tashiro H; Shindo T; Chiba S; Tomiyama J; Inokuchi K; Fukuda T
Int J Hematol; 2020 Aug; 112(2):200-209. PubMed ID: 32495317
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
[TBL] [Abstract][Full Text] [Related]
13. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
18. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
20. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
[Next] [New Search]